OBI Pharma To Forge Ahead With Cancer Vaccine In Face Of Study Failure

Taiwanese biotech OBI Pharma plans to plough on with a Phase III study of its investigational cancer vaccine OBI-822/821, despite it failing to meet the primary endpoint in a Phase II/III study. The firm's share price fell by from TWD681 to close at TWD613 on Feb. 22 and slipped a further 9.95% to close at TWD522 on Feb. 23 on Taiwan's GreTai Securities Market following the news.

Taiwanese biotech OBI Pharma plans to plough on with a Phase III study of its investigational cancer vaccine OBI-822/821, despite it failing to meet the primary endpoint in a Phase II/III study. The firm's share price fell by from TWD681 to close at TWD613 on Feb. 22 and slipped a further 9.95% to close at TWD522 on Feb. 23 on Taiwan's GreTai Securities Market following the news.

Top-line data show that the first-in-class product, described as an active immunotherapy, did not meet the primary efficacy endpoint of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By 

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.